Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Introduction: Inactivated poliovirus vaccine (IPV) introduction and phased oral poliovirus vaccine (OPV) cessation are essential for eradication of polio. Methods: Healthy 6-week old infants in Bangladesh were randomized to one of five study arms: receipt of trivalent OPV (tOPV) or bivalent OPV (bOPV) at ages 6, 10 and 14 weeks, intramuscular IPV or intradermal one-fifth fractional dose IPV (f-IPV) at ages 6 and 14 weeks, or f-IPV at ages 6 and 14 weeks with bOPV at age 10 weeks (f-IPV/bOPV). All participants received tOPV at age 18 weeks. Results: Of 975 infants randomized, 95% (922) completed follow-up. Type 1 seroconversion after 3 doses at 6, 10 and 14 weeks was higher with bOPV compared with tOPV (99% vs 94%, p = 0.019). Seroconversions to types 1 and 3 after 2 IPV doses at ages 6 and 14 weeks were no different than after 3 doses of tOPV or bOPV at ages 6, 10 and 14 weeks. A priming response, seroconversion 1 week after IPV at 14 weeks among those who did not seroconvert after IPV at 6 weeks, was observed against poliovirus types 1, 2 and 3 in 91%, 84% and 97%, respectively. Compared with IPV, f-IPV failed non-inferiority tests for seroconversion with 1 or 2 doses and priming after 1 dose. Discussion: The findings demonstrate considerable priming with IPV at age 6 weeks, comparable immunogenicity of tOPV and bOPV, and inferior immunogenicity of one-fifth f-IPV compared with IPV. If IPV induced priming at age 6 weeks is similar to that at age 14 weeks, IPV could be administered at a younger age and possibly with a higher coverage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: Review.
Patriarca, P. A., Wright, P. F., & John, T. J. (1991) · Clinical Infectious Diseases · doi:10.1093/clinids/13.5.926 · Cited by 453
Fine, P. E. M., & Carneiro, I. A. M. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009924 · Cited by 247
Randomized, Placebo-Controlled Trial of Inactivated Poliovirus Vaccine in Cuba
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa054960 · Cited by 90
Cited by
Microneedles as the technique of drug delivery enhancement in diverse organs and tissues
Rzhevskiy, A. S., Singh, T. R. R., Donnelly, R. F., & Anissimov, Y. G. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.048 · Cited by 266
Golombek, S., Pilz, M., Steinle, H., Kochba, E., Levin, Y., Lunter, D., Schlensak, C., Wendel, H. P., & Avci-Adali, M. (2018) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2018.03.005 · Cited by 88
Schnyder, J. L., De Pijper, C. A., Garcia Garrido, H. M., Daams, J. G., Goorhuis, A., Stijnis, C., Schaumburg, F., & Grobusch, M. P. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101868 · Cited by 74
Vaccination into the Dermal Compartment: Techniques, Challenges, and Prospects
Hettinga, J., & Carlisle, R. (2020) · Vaccines · doi:10.3390/vaccines8030534 · Cited by 72
Okayasu, H., Sein, C., Chang Blanc, D., Gonzalez, A. R., Zehrung, D., Jarrahian, C., Macklin, G., & Sutter, R. W. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix038 · Cited by 62
Metadata
- Authors
- Anand, A., Zaman, K., Estívariz, C. F., Yunus, M., Gary, H. E., Weldon, W. C., Bari, T. I., Steven Oberste, M., Wassilak, S. G., Luby, S. P., Heffelfinger, J. D., & Pallansch, M. A.
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2015-11
- Volume
- 33
- Issue
- 48
- Pages
- 6816-6822
- ISSN
- 0264-410X (ISSN-L)
- OpenAlex
- W1843762508
- Cited by
- 105
- References
- 3
- FWCI
- 9.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial. https://app.cochat.ai/papers/10.1016/j.vaccine.2015.09.039
- The paper
- Anand, A., Zaman, K., Estívariz, C. F., Yunus, M., Gary, H. E., Weldon, W. C., Bari, T. I., Steven Oberste, M., Wassilak, S. G., Luby, S. P., Heffelfinger, J. D., & Pallansch, M. A. (2015). Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial. Vaccine. https://doi.org/10.1016/j.vaccine.2015.09.039
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.